

Please amend claims 1-11 as follows:

1. (Amended) A method for the treatment of obesity which comprises administering to a patient in need of such treatment a reversible selective inhibitor of monoamine oxidase A, a reversible selective inhibitor of monoamine oxidase B or a reversible mixed inhibitor of monoamine oxidase A and B.

2. (Amended) A method according to claim 1 which comprises administering a reversible mixed inhibitor of monoamine oxidase A and B.

3. (Amended) A method according to claim 2 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen from [3(*S*),3a(*S*)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1*H*-oxazolo[3,4-*a*]quinolin-1-one, (*R*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (*R*)-5-(methoxymethyl-3-(6-cyclopropyl-methoxybenzofuran-3-yl)oxazolidin-2-one.

4. (Amended) A method according to claim 1 which comprises administering a reversible selective inhibitor of monoamine oxidase B.

5. (Amended) A method according to claim 4 wherein the reversible selective inhibitor of monoamine oxidase B is chosen among lazabemide, milacemide, caroxazone and IFO.

6. (Amended) A method according to claim 4 wherein the reversible selective inhibitor of monoamine oxidase B is (*S*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.

7. (Amended) A method according to claim 1 which comprises administering a reversible selective inhibitor of monoamine oxidase A.

8. (Amended) A method according to claim 7 wherein the reversible selective inhibitor of monoamine oxidase A is chosen from befloxatone, moclobemide, brofaromine, phenoxathine,

AB
"021502"
"021502"
"021502"

esuprone, befol, RS 8359, T794, KP9, E 2011, toloxatone, pirlindole, amiflamine, sercloremine and bazinaprime.

9. (Amended) A method according to claim 8 wherein the reversible selective inhibitor of monoamine oxidase A is befloxatone.

A3 10. (Amended) A method according to claim 9 wherein the dosage amount of befloxatone is from about 2.5 to 40 mg per day.

11. (Amended) A method according to claim 10 wherein the amount of befloxatome is from about 10 to 20 mg.

Please cancel claim 12.

Please add the following new claims:

13. (New) A method of decreasing body weight in a patient in need thereof which comprises administering to said patient an effective amount of a reversible selective inhibitor of monoamine oxidase A, a reversible selective inhibitor of monoamine oxidase B or a reversible mixed inhibitor of monoamine oxidase A and B.

AR 14. (New) A method according to claim 13 which comprises administering a reversible mixed inhibitor of monoamine oxidase A and B.

15. (New) A method according to claim 14 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen from [3(*S*),3a(*S*)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1*H*-oxazolo[3,4-*a*]quinolin-1-one, (*R*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (*R*)-5-(methoxymethyl-3-(6-cyclopropyl-methoxybenzofuran-3-yl)oxazolidin-2-one.

16. (New) A method according to claim 13 which comprises administering a reversible selective inhibitor of monoamine oxidase B.

17. (New) A method according to claim 16 wherein the reversible selective inhibitor of monoamine oxidase B is chosen among lazabemide, milacemide, caroxazone and IFO.

18. (New) A method according to claim 16 wherein the reversible selective inhibitor of monoamine oxidase B is (*S*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.

19. (New) A method according to claim 13 which comprises administering a reversible selective inhibitor of monoamine oxidase A.

20. (New) A method according to claim 19 wherein the reversible selective inhibitor of monoamine oxidase A is chosen from befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, RS 8359, T794, KP9, E 2011, tolloxatone, pirlindole, amiflamine, sercloremine and bazinaprine.

21. (New) A method according to claim 20 wherein the reversible selective inhibitor of monoamine oxidase A is befloxatone.

22. (New) A method according to claim 21 wherein the dosage amount of befloxatone is from about 2.5 to 40 mg per day.

23. (New) A method according to claim 22 wherein the amount of befloxatome is from about 10 to 20 mg.

2025-02-20 10:00:00